Jayesh Patel, MD
Geriatric Medicine · Macon, GANPI 1548385966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 300 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations.
Across 300 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$619
- Novo Nordisk$570
- GSK$543
- Lilly USA, LLC$499
- AbbVie$399
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,54999%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $1,179 |
| Pfizer | 29 | $619 |
| Novo Nordisk | 36 | $570 |
| GSK | 27 | $543 |
| Lilly USA, LLC | 37 | $499 |
| AbbVie(2 entities) | 22 | $399 |
| Amgen | 14 | $232 |
| Astellas Pharma US Inc | 12 | $202 |
| Boehringer Ingelheim | 12 | $197 |
| Abbott | 6 | $125 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Sanofi-aventis U.S. LLC | 7 | $101 |
| Sumitomo Pharma America, Inc. | 4 | $72 |
| Novartis | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $57 |
| Exact Sciences | 3 | $48 |
| Abiomed | 1 | $45 |
| Biogen | 2 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Urovant Sciences Inc | 2 | $39 |
| Merck | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Edwards Lifesciences | 1 | $32 |
| Bausch Health US, LLC | 2 | $31 |
| Bayer | 2 | $31 |
| Medtronic | 2 | $28 |
| Sun Pharmaceutical Industries Inc. | 2 | $26 |
| IBSA Pharma Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$471
How this compares
$5,613 in reported general payments places this provider in the 85th percentile of 75 geriatric medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 709 | $273,920 |
| OzempicSemaglutide | 88 | $152,389 |
| AustedoDeutetrabenazine | 12 | $88,835 |
| FarxigaDapagliflozin Propanediol | 113 | $69,013 |
| JardianceEmpagliflozin | 65 | $61,394 |
| TrulicityDulaglutide | 33 | $53,174 |
| MounjaroTirzepatide | 21 | $51,408 |
| EntrestoSacubitril/Valsartan | 65 | $46,782 |
| XifaxanRifaximin | 55 | $44,803 |
| MyrbetriqMirabegron | 169 | $38,437 |
| RybelsusSemaglutide | 18 | $35,385 |
| XareltoRivaroxaban | 117 | $33,064 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $28,506 |
| RexultiBrexpiprazole | 47 | $27,385 |
| LinzessLinaclotide | 29 | $17,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $619 | $273,920709 claims |
| Novo NordiskOzempic, Rybelsus | $570 | $187,774106 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $499 | $104,58254 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,179 | $90,065141 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $36 | $88,83512 claims |
| Boehringer IngelheimJardiance | $197 | $61,39465 claims |
| NovartisEntresto | $66 | $46,78265 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $543 | $39,85663 claims |
| Astellas Pharma US IncMyrbetriq | $202 | $38,437169 claims |
| Johnson & JohnsonXarelto | $16 | $33,064117 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $104 | $27,38547 claims |
| AbbVieLinzess | $399 | $17,67329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 geriatric medicine providers in Georgia.
Other geriatric medicine in Macon
- Harry StrothersMacon$10K
- Richard AckermannMacon$43
- Joseph MiccaMarietta$130K
- Monica ParkerAtlanta$74K
- Daniel DinoSt Marys$13K
- Wayne MorrisAthens$12K
- Scott MikellStatesboro$10K
- Theodore JohnsonAtlanta$6K
- Anitha KoduruEvans$6K
- Sudeshna NandiDuluth$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.